Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Operating expenses: | |||
| Research and development | $456,660 | $360,917 | $212,928 |
| Acquired in-process research and development | — | — | 12,500 |
| General and administrative | 76,242 | 77,235 | 57,281 |
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s G&A?
- Immunovant, Inc. (IMVT) reported G&A of $17.27M in Q1 2026.
- How has Immunovant, Inc.'s G&A changed year-over-year?
- Immunovant, Inc.'s G&A decreased by 14.4% year-over-year, from $20.17M to $17.27M.
- What is the long-term trend for Immunovant, Inc.'s G&A?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s G&A has grown at a 8.9% compound annual growth rate (CAGR), from $54.23M to $76.24M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Immunovant, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude